Agilent Technologies Inc. (A) - NYSE
  • Mon, May 23, 12:39 PM
    • "Politics is now a topic in every client discussion," say David Kostin and team, and the nature of today's electorate nearly assures a close race, even though prediction markets currently assign a high probability of a Clinton victory.
    • When uncertainty rises, consumer staples (NYSEARCA:XLP) typically outperforms, while tech (NYSEARCA:XLK) lags.
    • Getting down to names, with protectionism and tax policy two key areas of debate, buy those stocks with high U.S. sales and high effective tax rates, and avoid those with high foreign sales and low tax rates.
    • High U.S. sales and high tax rates (buy): Cardinal Health (NYSE:CAH), Fidelity National (NYSE:FIS), Discover (NYSE:DFS), AmerisourceBergen (NYSE:ABC), Schwab (NYSE:SCHW), ADP (NASDAQ:ADP), Chipotle (NYSE:CMG), Reynolds America (NYSE:RAI), Express Scripts (NASDAQ:ESRX), Alliance Data (NYSE:ADS), Fiserv (NASDAQ:FISV), Paychex (NASDAQ:PAYX), Whole Foods (NASDAQ:WFM), Akamai (NASDAQ:AKAM), Intuit (NASDAQ:INTU), Southwest Airlines (NYSE:LUV).
    • High foreign sales and low tax rates (avoid): Abbott Labs (NYSE:ABT), Agilent (NYSE:A), Mondelez (NASDAQ:MDLZ), XL Group (NYSE:XL), Waters (NYSE:WAT), Priceline (NASDAQ:PCLN), Transocean (NYSE:RIG), PerkinElmer (NYSE:PKI), Nvidia (NASDAQ:NVDA), Lam Research (NASDAQ:LRCX), Western Digital (NASDAQ:WDC).
    | Mon, May 23, 12:39 PM | 18 Comments
  • Wed, May 18, 4:25 PM
    • Agilent Technologies Inc. (NYSE:A) declares $0.115/share quarterly dividend, in line with previous.
    • Forward yield 1.04%
    • Payable July 27; for shareholders of record July 5; ex-div June 30.
    | Wed, May 18, 4:25 PM
  • Mon, May 16, 4:33 PM
    • Agilent (NYSE:A) is up 3.3% after beating on top and bottom lines in its Q1 earnings and raising full-year expectations above consensus.
    • For the full year, the company forecasts revenue of $4.16B-$4.18B (above consensus for $4.13B) and non-GAAP EPS of $1.88-$1.94, above expectations for $1.86.
    • Income from continuing operations was $145M on a non-GAAP basis, up 12.4%.
    • Revenue by segment: Life Sciences and Applied Markets, $495M (up 5%); CrossLab Group, $346M (up 8%); Diagnostics and Genomics, $178M (up 5%).
    • The company expects Q3 revenues of $1.03B-$1.05B (in line) and EPS of $0.45-$0.47 (vs. expected $0.47).
    • Conference call to come at 4:30 p.m. ET.
    • Press Release
    | Mon, May 16, 4:33 PM
  • Mon, May 16, 4:07 PM
    • Agilent (NYSE:A): Q1 EPS of $0.44 beats by $0.05.
    • Revenue of $1.02B (+5.9% Y/Y) beats by $36.74M.
    • Shares +1.6%.
    • Press Release
    | Mon, May 16, 4:07 PM | 4 Comments
  • Sun, May 15, 5:35 PM
    | Sun, May 15, 5:35 PM | 1 Comment
  • Wed, Mar. 16, 4:34 PM
    • Agilent Technologies Inc. (NYSE:A) declares $0.115/share quarterly dividend, in line with previous.
    • Forward yield 1.18%
    • Payable April 27; for shareholders of record April 5; ex-div April 1.
    | Wed, Mar. 16, 4:34 PM
  • Tue, Feb. 16, 4:07 PM
    • Agilent (NYSE:A): FQ1 EPS of $0.46 beats by $0.03.
    • Revenue of $1.03B (flat Y/Y) beats by $10M.
    • Shares -2.9%.
    • Press Release
    | Tue, Feb. 16, 4:07 PM
  • Mon, Feb. 15, 5:35 PM
    | Mon, Feb. 15, 5:35 PM | 4 Comments
  • Wed, Jan. 6, 10:23 AM
    • Agilent Technologies (A -0.2%) will pay Enzo Biochem (ENZ -1.1%) $9M to settle an infringement suit related to Enzo's U.S. Patent No. 7,064,197, the third resolution of 11 brought by Enzo against different companies. Eight cases remain pending.
    • The patent pertains to technology used in nucleic acid detection.
    | Wed, Jan. 6, 10:23 AM
  • Nov. 19, 2015, 4:28 PM
    • Agilent (NYSE:A) declares $0.115/share quarterly dividend, 15% increase from prior dividend of $0.10.
    • Forward yield 1.19%
    • Payable Jan. 27; for shareholders of record Jan. 5; ex-div Dec. 31.
    | Nov. 19, 2015, 4:28 PM
  • Nov. 16, 2015, 4:35 PM
    • Agilent (A +1.5%fiscal Q4 results ($M): Net Revenues: 1,035 (-0.8%); Life Sciences and Applied Markets Group: 515 (-4.5%); Diagnostics and Genomics Group: 178 (+3.5%); Agilent CrossLab Group: 342 (+3.0%).
    • Operating Income: 156 (+122.9%); Net Income: +(508.7%); Non-GAAP Net Income: 168 (+4.3%); EPS: 0.42 (+500.0%); Non-GAAP EPS: 0.50 (+4.2%); CF Ops: 237.
    • Fiscal Q1 Guidance: Revenues: $1.0B - 1.02B; Non-GAAP EPS: $0.42 - 0.44.
    • Fiscal 2016 Guidance: Revenues: Revenues: $4.15B - 4.17B; Non-GAAP EPS: $1.85 - 1.91.
    • Shares are down 2% after hours on modest volume.
    | Nov. 16, 2015, 4:35 PM | 1 Comment
  • Nov. 16, 2015, 4:06 PM
    • Agilent (NYSE:A): FQ4 EPS of $0.50 beats by $0.03.
    • Revenue of $1.04B (-.8% Y/Y) in-line.
    | Nov. 16, 2015, 4:06 PM
  • Nov. 15, 2015, 5:35 PM
  • Nov. 5, 2015, 11:13 AM
    • Agilent (A -0.8%) announces a formal agreement with Thermo Fisher Scientific for the exchange of instrument controls for customers using software and instruments from both companies.
    • The companies are also providing technical assistance to each other's software development groups.
    | Nov. 5, 2015, 11:13 AM
  • Oct. 2, 2015, 3:44 PM
    • The FDA approves Merck's (MRK +1.1%) Keytruda (pembrolizumab) for the treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and that express a protein called PD-L1 [such as Bristol-Myers Squibb's (BMY +3.2%) Opdivo (nivolumab)].
    • The data supporting the sBLA was generated from a subgroup of 61 NSCLC patients within a larger study who progressed following platinum-based chemo and targeted therapies for EGFR/ALK mutations, if present. The subgroup's tumors all expressed PD-L1 as determined by the 22C3 pharmDx companion diagnostic test. Participants received 10 mg/kg of Keytruda every two to three weeks. The results showed that treatment with Keytruda shrank tumors in 41% of patients with the effect lasting as long as 9.1 months.
    • The FDA designated Keytruda a Breakthrough Therapy for this indication.
    • Reference labs Quest Diagnostics (DGX +2%) and LabCorp (LH +1.9%) will offer the 22C3 pharmDx test as a service. The kit was developed by Agilent's (A +2.7%) Dako unit.
    | Oct. 2, 2015, 3:44 PM | 11 Comments
  • Sep. 16, 2015, 4:10 PM
    • Agilent (NYSE:A) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.1%
    • Payable Oct. 21; for shareholders of record Sept. 29; ex-div Sept. 25.
    | Sep. 16, 2015, 4:10 PM
Company Description
Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics, diagnostics and genomics industries. It operates through the following segments: Life Sciences, Chemical Analysis, Diagnostics &... More
Industry: Industrial Equipment & Components
Country: United States